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Abstract
Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease. The interleukin-6 (IL-6) receptor
antagonist tocilizumab has been shown to lower serum Lp(a) concentrations. We investigated whether the IL-6 single
nucleotide polymorphism 2174G/C is associated with baseline serum Lp(a) concentrations.
Methodology/Principal Findings: We divided 2321 subjects from the Lipid Analytic Cologne (LIANCO) cohort into 2 groups,
the ones with substantially elevated Lp(a), defined as concentrations $60 mg/dl (n=510), and the ones with Lp(a) ,60 mg/
dl (n=1811). The association with the genotypes GG (33.7%), GC (50.75%) and CC (15.55%) was investigated. The GC and
the CC genotype were associated with a significantly increased odds ratio of having substantially elevated Lp(a)
concentrations (OR=1.3, 95% CI 1.04 to 1.63, P=0.02 and OR=1.44, 95% CI 1.06 to 1.93, P=0.018). These associations
remained significant after adjusting for age, sex, smoking behavior, body mass index, serum lipoproteins, hypertension and
diabetes. Of these covariates, only LDL cholesterol was significantly and independently associated with elevated Lp(a)
concentrations.
Conclusions/Significance: The IL-6 single nucleotide polymorphism 2174G/C is associated with increased odds of having
elevated Lp(a). Whether this association plays a role in the Lp(a)-lowering effects of IL-6 receptor antagonists remains to be
established.
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Introduction
Lipoprotein(a) [Lp(a)] has been considered a cardiovascular risk
factor for many years [1]. Together with recent genetic findings
and based on robust and specific associations between elevated
Lp(a) concentrations and increased cardiovascular disease risk, it is
now accepted that Lp(a) is causally related to premature
cardiovascular disease [2]. A European Atherosclerosis Society
Consensus Panel recommends screening for elevated Lp(a) for all
patients at intermediate or high cardiovascular risk [2]. Moreover,
the panel points to the need for randomized controlled
intervention trials with selective reduction in plasma Lp(a)
concentrations to reduce cardiovascular disease in both primary
and secondary prevention settings, as they are urgently required to
define more precisely whom to treat and to what target levels [2].
There is no generally accepted drug treatment for Lp(a)
lowering, although some drugs have been described to be effective
[3]. Among these are niacin [4], the cholesteryl ester transfer
protein (CETP) inhibitor anacetrapib [5], the thyroid hormone
analogue eprotirome [6], the apoB synthesis inhibitor mipomersen
[7], and hormone replacement therapy or raloxifene, among
others [3]. However, no specific therapy primarily targeting Lp(a)
is available and no study until now has shown that selectively
decreasing Lp(a) will decrease cardiovascular disease risk.
A recent study from our group revealed that the humanized
monoclonal antibody against the interleukin-6 (IL-6) receptor,
tocilizumab, decreased Lp(a) concentrations in humans [8].
Tocilizumab is approved for the treatment of rheumatoid arthritis
and inhibition of IL-6 signaling seems to have multiple metabolic
effects, e.g. decreasing insulin resistance. Variations caused by IL-6
promoter polymorphisms are associated with diabetes mellitus,
obesity and several features of the metabolic syndrome [9]. The
IL-6 gene single nucleotide polymorphism (SNP) 2174G/C of the
59 flanking region influences plasma levels of IL-6 [10–12]. Based
on our discovery that the IL-6 antibody tocilizumab decreases
Lp(a), we proceeded to investigate whether the presence of this
SNP is associated with baseline Lp(a) concentrations in humans.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24719We were able to confirm our hypothesis that the SNP 2174G/C
predisposes to elevated Lp(a) levels.
Methods
Study design and subjects
The subjects were obtained from the LIANCO database (Lipid
Analytic Cologne) [13,14]. In brief, LIANCO was designed to assess
the relationship between genetic mutations, serum lipoproteins,
other biochemical parameters, and clinical data on atherosclerotic
disease, hypertension and diabetes. Approval of the study protocol
was obtained from the ethics committee of the medical faculty of
the University of Cologne (http://www.medfak.uni-koeln.de/179.
html).
Written informed consent was obtained from all subjects. The
ethics committee approved the LIANCO study but did not
specifically approve the current retrospective study. However, the
current study is fully covered by the ethics committee’s vote. The
study was performed doing a reanalysis of existing LIANCO data,
i.e. there were no de novo experiments on the subjects. Institutional
Review Board (IRB) approval for this study was obtained prior to
creating the LIANCO registry.
Between spring 1999 and March 2002 a total of about 5000
patients were recruited in the Cologne (Germany) area by
hospitals and office-based physicians. Patients’ data were recorded,
their lipoproteins analyzed and samples frozen for DNA
extraction.
Lp(a) was measured using an immunoturbidimetric assay [15]
using a COBAS INTEGRA 400 analyser (Roche Diagnostics,
Mannheim, Germany). The intra-assay coefficient of variation was
0.7–2.3% and the inter-assay coefficient of variation was 2.9–
3.3%.
Lp(a) measurements were available in 3904 subjects and
determination of the 2174G/C SNP in 2490 subjects. A total of
2321 subjects participated in the current study, the ones in whom
both measurements were available. Lp(a) concentrations were
similar in the total (n=3904) and in the participating (n=2321)
cohort (median [interquartile range] 19.0 [45.0] or 18.0 [42.0]
mg/dl , respectively). Genotype frequencies were also similar
between the total (n=2490) and the participating (n=2321) cohort
(GG, GC and CC 33.49%, 50.88% and 15.62% or 33.49%,
50.87% and 15.64%, respectively).
Atherosclerotic disease was defined as the presence and/or
history of $1 of the following: history of stroke, transient ischemic
attack, prolonged ischemic neurological deficit, coronary heart
disease (CHD), and peripheral vascular disease (PAD). CHD was
defined as the presence of $1 of the following: angiographic
evidence of CHD, myocardial infarction, angina pectoris,
coronary bypass surgery or positive stress test. Hypertension was
defined as known or newly diagnosed hypertension according to
current national guidelines, i.e. systolic blood pressure values
.140 mmHg or diastolic values .90 mmHg. If hypertension was
controlled by medication, patients were still considered hyperten-
sive, irrespective of their blood pressure readings.
Detection of the 2174G/C polymorphism
Genomic DNA was prepared from peripheral blood using
standard techniques. The 2174G/C SNP was detected by PCR
followed by restriction fragment length polymorphism as previ-
ously described [16]. In short, a 198 bp fragment of the IL-6 gene
was amplified. Forward and reverse primer sequences were 59-
TGACTTCAGCTTTACTCTTTGT-39 and 59-CTGATTG-
GAAACCTTATTAGG-39, respectively. Each PCR cycle con-
sisted of denaturation for 60 seconds at 94uC, annealing for
95 seconds at 55uC, and extension for 60 seconds at 72uC,
followed by a final extension at 72uC for nine minutes. PCR
products were digested with SfaNI (Fermentas, St. Leon-Rot,
Germany) and separated by electrophoresis in 3% agarose. The
presence of a single 198 bp band corresponds to the CC genotype;
bands at 140 and 58 bp correspond to the GG genotype and the
presence of three bands corresponds to the GC genotype.
The PCR products were automatically sequenced (ABI Prism
Genetic Analyzer model 310, Applied Biosystems, Foster City,
CA). The sequence of both strands was determined.
Quality checks to ensure correctness of the genotypes were
carried out by independent rating of the results by two
investigators. Discrepancies were resolved by either reaching
consensus or re-genotyping.
Statistical analysis
Statistical analysis was carried out using Stata Version 11
(StataCorp LP, College Station, TX). Statistical significance was
defined as P,0.05 and all tests were performed 2-sided.
Descriptive statistics are given, unless otherwise indicated, as
mean 6 SD. Comparison of mean values was performed by
unpaired Student’s t-test. Chi square P values were calculated to
test for differences in allele and genotype frequencies and in
categorical variables. Allele frequencies were estimated by gene
counting.
Two-way analysis of variance was used to establish the influence
of categorical variables on continuous parameters. A logistic
modeling approach was used to investigate parameters that may
be associated with the presence of hypertension, diabetes, or
atherosclerotic disease. Multiple logistic regression was used to
adjust for the effects of sex, age, body mass index (BMI), and
smoking. Lp(a) and triglyceride values were log-transformed before
statistical analysis. Original rather than log-transformed values are
presented in the results for clarity.
Results
Study cohort and biochemical analysis
The characteristics of the 2321 study subjects are presented in
Table 1. There were 1811 subjects with Lp(a) ,60 mg/dl and
510 subjects with Lp(a) $60 mg/dl. The level of Lp(a) $60 mg/dl
was chosen as a cut-off based on the significantly increased risk for
CHD above this level, as observed in several recent studies [17–
19]. There were no differences between the groups in sex
distribution, age, smoking behavior, blood pressure or the
presence of hypertension. BMI was lower in the group with
higher Lp(a). Total cholesterol, LDL and HDL cholesterol
concentrations were higher while triglycerides were lower in this
group. There were no differences in lipid-lowering medication use.
The rate of atherosclerotic disease was significantly higher in the
high Lp(a) group (28 vs. 18%), while the prevalence of diabetes was
lower (13 vs. 18%). Of the 2321 study subjects, 687 (29.6%) had
Lp(a) concentrations ,10 mg/dl, 781 (33.6%) had Lp(a) $10 and
,30 mg/dl, 343 (14.8%) had Lp(a) $30 and ,60 mg/dl, 267
(11.4%) had Lp(a) $60 and ,100 mg/dl and 243 (10.5%) had
Lp(a) $100 mg/dl.
Genotyping of the 2174G/C polymorphism in the study
cohort
The allele frequencies of the G and C allele in the whole study
population were 59.1% G and 40.9% C, respectively, whereas the
matching genotype frequencies were 33.7% GG, 50.75% GC and
15.55% CC. The data are shown in Table 2. Genotype
frequencies in the total study population were marginally
IL-6 Polymorphism 2174G/C and Lp(a) Concentrations
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P=0.017), while the two groups considered separately were in
agreement with HWE (low Lp(a) group chi square P=0.08, high
Lp(a) group chi square P=0.06).
Influence of the 2174G/C SNP on Lp(a) concentrations
In the total cohort, there were differences in Lp(a) concentrations
depending on genotype. The mean 6 SD concentrations were
35.2646.9 mg/dl, 37.9651.2 mg/dl, and 40.3655.3 mg/dl for
the GG, GC, and CC genotype, respectively. The corresponding
geometric means (95% CI) were 15.9 (14.4 to 17.5) mg/dl, 16.9
(15.6 to 18.3) mg/dl, and 18.5 (15.9 to 21.4) mg/dl, respectively (P
for trend 0.042). We analyzed the effects of the 2174G/C SNP on
Lp(a) concentration using logistic regression analysis. The GC and
CC genotypes were associated with a higher odds ratio for the
prevalence of elevated Lp(a), defined as concentrations $60 mg/dl.
For GC the odds ratio was 1.30 (95% CI 1.04 to 1.63, P=0.02) and
for CC the odds ratio was 1.44 (95% CI 1.06 to 1.93, P=0.018).
When taken together, the C-carriers had an odds ratio of 1.33 (95%
CI 1.08 to 1.65, P=0.009) compared to the GG wildtype.
Influence of the 2174G/C SNP on other parameters
Using analysis of variance we investigated whether the polymor-
phism influenced other continuous parameters. For simplicity, we
divided the subjects in the ones having the GG wildtype (reference
group) and the ones carrying the C-allele. The polymorphism was






P value (Lp(a) ,60
vs. $60 mg/dl)
Sample size 2321 1811 (78.0%) 510 (22.0%)
Male 1248 (53.8%) 977 (53.9%) 271 (53.1%) 0.75*
Age (years) 56.9612.4 56.9612.3 57.0612.6 0.96**
Smoking Never 1634 (70.4%) 1269 (70.1%) 365 (71.6%)
Former 198 (8.5%) 156 (8.6%) 42 (8.2%)
Current 488 (21.0%) 385 (21.3%) 103 (20.2%)
Body mass index (kg/m
2)2 7 . 0 64.4 27.264.5 26.464.1 0.0003**
Atherosclerotic disease 473 (20.4%) 331 (18.3%) 142 (27.8%) ,0.0001*
Total cholesterol (mg/dl) 257663 255663 262661 0.022**
LDL cholesterol (mg/dl) 162650 160650 168649 0.003**
HDL cholesterol (mg/dl) 59617 56617 59617 0.0003**
Triglycerides (mg/dl) 2046226 2106236 1846184 0.0004**
Median (IQR) 149 (129) 153 (131) 135 (117)
Lipoprotein(a) (mg/dl) 38651 17615 113661 ,0.0001**
Median (IQR) 19 (46) 13 (19) 96 (63)
Lipid lowering medication 229 (9.9%) 181 (10.0%) 48 (9.4%) 0.19*
Systolic blood pressure (mmHg) 137619 137619 136620 0.74**
Diastolic blood pressure (mmHg) 83610 83610 82610 0.60**
Hypertension 1139 (49.0%) 888 (49.0%) 251 (49.2%) 0.94*
Diabetes mellitus 394 (17.0%) 329 (18.2%) 65 (12.7%) 0.004*
Quantitative variables are presented as mean 6 standard deviation and median and interquartile range (IQR) where appropriate; counts are given as n and percent.
*Chi-square P value.
**Unpaired Student’s t-test (the data of Lp(a) and triglycerides were log-transformed before analysis).
doi:10.1371/journal.pone.0024719.t001
Table 2. Genotype distribution of the 2174G/C SNP between subjects with lower (,60 mg/dl) or higher ($60 mg/dl) Lp(a) levels.
Subjects GG GC CC Chi square P value
Total cohort (n=2321) 782 (33.7%) 1178 (50.75%) 361 (15.55%) 0.024
Lp(a) ,60 mg/dl (n=1811) 635 (35.1%) 905 (50.0%) 271 (14.9%)
Lp(a) $60 mg/dl (n=510) 147 (28.8) 273 (53.5%) 90 (17.6%)
GG C-carriers
Total cohort (n=2321) 782 (33.7%) 1539 (66.3%) 0.008
Lp(a) ,60 mg/dl (n=1811) 635 (35.1%) 1176 (64.9%)
Lp(a) $60 mg/dl (n=510) 147 (28.8%) 363 (71.2%)
doi:10.1371/journal.pone.0024719.t002
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(P=0.92), LDL cholesterol (P=0.63), HDL cholesterol (P=0.44),
systolic or diastolic blood pressure (P=0.19 or 0.36, respectively). It
was significantly associated with triglycerides (P=0.04), in that C-
carriers had slightly higher triglyceride levels.
Using contingency tables and chi square statistics we investi-
gated the association between the polymorphism and categorical
data. There was no association with the presence of atherosclerosis
(P=0.62), diabetes (P=0.61), or hypertension (P=0.17).
Multiple logistic regression analysis
In multiple logistic regression analysis using the presence of high
Lp(a) concentrations as the dependent and age, sex, smoking,
BMI, lipid concentrations, hypertension and diabetes as covariates
we found that the polymorphism remained independently
associated with high Lp(a) concentrations (odds ratio of the C-
carriers 1.35, 95% CI 1.08 to 1.69, P=0.009). The only significant
covariate was LDL that also exerted an independent significant
influence on Lp(a) concentrations.
Discussion
The main finding of this study is that the common 2174G/C
polymorphism of the IL-6 gene is significantly associated with the
risk of elevated Lp(a) concentrations ($60 mg/dl).
Low grade inflammation has been shown to be important in the
pathogenesis of atherosclerosis in cell lines, animal models and
humans [20]. Of the many cytokines examined in this context, IL-6
exhibits a strong association not only with cardiovascular mortality
itself [21] but also with cardiovascular risk factors like type 2
diabetes [22,23], hypertension [24] and lipid abnormalities [25].
IL-6 is a pro-inflammatory cytokine with a molecular weight of
26 kD. The receptor of this signaling protein consists of two
subunits, gp130 and IL-6 receptor-alpha (IL-6-R-a), and is linked
to the Janus kinase (JAK) – signal transducer and activator of transcription
(STAT) signaling cascade [26]. Interestingly, in addition to this
classical signaling pathway, IL-6 can also act via the so called
‘‘trans-signaling’’, whereby IL-6 binds to a soluble IL-6-R-a, thus
activating cells only expressing the gp130 protein at the cell surface
[27]. Furthermore, it has been shown that the suppressor of cytokine
signaling (SOCS)-3, a protein known to impair insulin signaling, is
induced by the JAK-STAT signaling pathway, suggesting a
molecular mechanism by which IL-6 exerts metabolic effects [28].
A common SNP in the human IL-6 gene, 2174G/C, has been
associated with altered serum levels of this pro-inflammatory cytokine
in humans, with carriers of the C-allele exhibiting higher serum levels
of IL-6 in some [29] but not all [30] studies. However, whether the
2174G/C polymorphism is associated with IL-6 concentrations is
unclear. A number of studies examining this association produced
widely discrepant results with some studies showing an association
[29,31–34], while many did not [30,35–37]. Also, carriers of the C-
allele show significantly higher C-reactive protein (CRP) levels
compared to carriersof the G-allele[38], which isof interestsince IL-
6 is one of the major determining factors of CRP levels in humans. In
agreement with the association studies on IL-6 serum levels and
cardiovascular disease mentioned above, carriers of the C-allele have
been shown to have a higher risk for coronary heart disease [39] and
stroke [40] and also show a higher prevalence of risk factors like
hypertension [41] and type 2 diabetes [42]. Moreover, in a cohort of
285 nonagenarians, the frequency of the ‘‘protective’’ G-allele was
significantly associated with longevity, indicating a clinical signifi-
cance of this common IL-6 polymorphism [43].
Using the humanized IL-6 receptor antibody tocilizumab we
recently demonstrated an approximately 30% reduction of serum
Lp(a) levels due to inhibition of IL-6 signaling in humans [8]. The
higher frequency of the C-allele at the 2174 locus in the IL-6 gene
in human subjects with elevated Lp(a) levels reported here is in
complete agreement with these findings, since the C-allele at this
locus is associated with higher IL-6 serum levels [29]. Further-
more, an earlier study suggested regulation of Lp(a) serum levels
by acute phase response (APR), for which IL-6 is crucial [44]. Taken
together, these findings suggest that IL-6 is a major determining
factor of serum Lp(a) levels in human subjects.
Despite evidence from previous reports [42], we did not find in
our cohort a significant association of the 2174G/C polymor-
phism with type 2 diabetes. In this respect it is important to note
that our cohort was not collected to examine genetic influence on
diabetes development but to identify target genes involved in
severe dyslipidemia. Therefore, the study cohort does not reflect a
representative population of type 2 diabetic subjects. Furthermore,
it should be mentioned that an independent association of the
2174G/C polymorphism with type 2 diabetes risk was found in
several reports, but not in the largest of such studies performed in
Denmark in 2005 [9]. Therefore, the potential role of the 2174G/
C SNP in the pathogenesis of type 2 diabetes remains
controversial. Moreover, we found no association of the SNP
with BMI, which is in agreement with previous reports [45].
Besides influencing Lp(a) levels, we also found significantly
higher serum triglyceride concentrations in carriers of the C-allele
at the 2174 locus of the human IL-6 gene. This is of interest, since
studies in rodents suggest that IL-6 treatment increased hepatic
triglyceride secretion without decreasing the clearance of triglyc-
eride-rich lipoproteins [46]. Furthermore, apolipoprotein B, which
is important for the formation of very-low-density lipoprotein
(VLDL) particles, has been found to be secreted from hepatocytes
in response to IL-6 treatment [47]. Moreover, our findings are in
agreement to those of Henningsson et al., who showed that male
carriers of the C allele displayed elevated serum triglycerides [48].
We also observed that Lp(a) levels are inversely associated with the
risk of type 2 diabetes, an interesting finding recently also reported
by the group of Ridker et al. [49]. Moreover, we observed that
Lp(a) concentrations are associated with LDL-, total- and HDL-
cholesterol concentrations, in accordance to previous reports
[50,51]. The inverse association between triglyceride levels and
BMI with Lp(a) levels found in the present study is in agreement
with the findings of Chien et al. [52], although the association of
Lp(a) levels with BMI remains controversial [53].
Taken together, the positive association of the C-allele at the
2174 locus of the human IL-6 gene with elevated Lp(a)
concentrations together with the Lp(a)-decreasing effects of the
IL-6 antagonist tocilizumab strongly suggests that Lp(a) serum
levels are regulated by IL-6 in humans. Since presently the
number of drugs to treat elevated Lp(a) levels in patients with
cardiovascular diseases is limited [54], these findings may open an
interesting field for biomedical research in order to develop novel
pharmacological strategies for affected patients.
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